검색으로 10,000+ 프로그램 중 최대 5개를 골라 PK/PD · 독성 · 임상을 나란히 비교합니다. · 다음 갱신 D-13 · 마지막 7월 21일
현재 선택: 4개 · 임상 갱신 필요 2개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | ||||
|---|---|---|---|---|
Overview Program | Cosentyx (secukinumab) | Secikinumab | Ixekizumab | AIN457 (secukinumab) |
Overview Company | Novartis | Novartis Pharmaceuticals | Eli Lilly and Company | Novartis |
Overview Modality | ANTIBODY | ANTIBODY | ANTIBODY | ANTIBODY |
Overview Target | IL-17A | Psoriasis | Psoriatic Arthritis | Psoriatic Arthritis |
Overview Indication | Psoriasis, psoriatic arthritis, ankylosing spondylitis | Axial Spondylarthritis (axSpA); Secukinumab | Psoriasis; Atopic Dermatitis | Asthma |
Overview Phase | APPROVED | PRECLINICAL | APPROVED | PHASE_3 |
Overview Status | APPROVED | ACTIVE | RECRUITING | ACTIVE |
MoA Mechanism | Targeted immunotherapies provide effective interventions by disrupting these cytokine-driven pathway | — | targets and signaling pathway | Targeted immunotherapies provide effective interventions by disrupting these cytokine-driven pathway |
MoA Biomarker | biomarkers and optimize therapeutic strategies | — | — | biomarkers and optimize therapeutic strategies |
PK/PD Half-life | 31 h | — | 13 h | 31 h |
PK/PD Species | Mouse, Human | — | Mouse | Rat, Human |
PK/PD Animal (cat.) | Human, Mouse | — | Mouse | Human, Rat |
PK/PD Experiment | Pharmacokinetic | — | pharmacokinetic | pharmacokinetic |
Toxicology Species | Mouse, Human | — | Mouse | Mouse, Rat, Human |
Toxicology Animal (cat.) | Mouse | — | Mouse | Mouse |
Toxicology Major finding | — | — | Ixekizumab Treatment Persistence in Psoriatic Arthritis: Response to Joaquin et al.. We appreciate the interest of Joaquin et al in our recent study on the treatment persistence of ixekizumab in psoriatic arthritis. In response, we clarify that our study utilized prospectively collected real-world clinical data from a multicenter observational cohort, rather than administrative databases. We empha… | — |
Clinical Primary efficacy | ORR 78.1% | — | — | ORR 53% |
Clinical PASI75 | — | — | — | PASI 90 responders at Week 24 that secukinum |
Clinical ORR | 78.10% | — | — | 53% |
Clinical Result source | ClinicalTrials.gov NCT04732117 | — | — | ClinicalTrials.gov NCT02409667 |
Clinical Data Tier / Score | S · 91 | C · 0 | C · 42 | B · 57 |
Clinical Program phase | APPROVED | PRECLINICAL | APPROVED | PHASE_3 |
Clinical Clinical sync | 2026년 7월 18일 (3일 전) | 2026년 5월 22일 (61일 전 · 갱신 권장) | 2026년 7월 9일 (13일 전) | 2026년 7월 8일 (14일 전 · 갱신 권장) |
검색으로 10,000+ 프로그램 중 최대 5개를 골라 PK/PD · 독성 · 임상을 나란히 비교합니다. · 다음 갱신 D-13 · 마지막 7월 21일
현재 선택: 4개 · 임상 갱신 필요 2개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | ||||
|---|---|---|---|---|
Overview Program | Cosentyx (secukinumab) | Secikinumab | Ixekizumab | AIN457 (secukinumab) |
Overview Company | Novartis | Novartis Pharmaceuticals | Eli Lilly and Company | Novartis |
Overview Modality | ANTIBODY | ANTIBODY | ANTIBODY | ANTIBODY |
Overview Target | IL-17A | Psoriasis | Psoriatic Arthritis | Psoriatic Arthritis |
Overview Indication | Psoriasis, psoriatic arthritis, ankylosing spondylitis | Axial Spondylarthritis (axSpA); Secukinumab | Psoriasis; Atopic Dermatitis | Asthma |
Overview Phase | APPROVED | PRECLINICAL | APPROVED | PHASE_3 |
Overview Status | APPROVED | ACTIVE | RECRUITING | ACTIVE |
MoA Mechanism | Targeted immunotherapies provide effective interventions by disrupting these cytokine-driven pathway | — | targets and signaling pathway | Targeted immunotherapies provide effective interventions by disrupting these cytokine-driven pathway |
MoA Biomarker | biomarkers and optimize therapeutic strategies | — | — | biomarkers and optimize therapeutic strategies |
PK/PD Half-life | 31 h | — | 13 h | 31 h |
PK/PD Species | Mouse, Human | — | Mouse | Rat, Human |
PK/PD Animal (cat.) | Human, Mouse | — | Mouse | Human, Rat |
PK/PD Experiment | Pharmacokinetic | — | pharmacokinetic | pharmacokinetic |
Toxicology Species | Mouse, Human | — | Mouse | Mouse, Rat, Human |
Toxicology Animal (cat.) | Mouse | — | Mouse | Mouse |
Toxicology Major finding | — | — | Ixekizumab Treatment Persistence in Psoriatic Arthritis: Response to Joaquin et al.. We appreciate the interest of Joaquin et al in our recent study on the treatment persistence of ixekizumab in psoriatic arthritis. In response, we clarify that our study utilized prospectively collected real-world clinical data from a multicenter observational cohort, rather than administrative databases. We empha… | — |
Clinical Primary efficacy | ORR 78.1% | — | — | ORR 53% |
Clinical PASI75 | — | — | — | PASI 90 responders at Week 24 that secukinum |
Clinical ORR | 78.10% | — | — | 53% |
Clinical Result source | ClinicalTrials.gov NCT04732117 | — | — | ClinicalTrials.gov NCT02409667 |
Clinical Data Tier / Score | S · 91 | C · 0 | C · 42 | B · 57 |
Clinical Program phase | APPROVED | PRECLINICAL | APPROVED | PHASE_3 |
Clinical Clinical sync | 2026년 7월 18일 (3일 전) | 2026년 5월 22일 (61일 전 · 갱신 권장) | 2026년 7월 9일 (13일 전) | 2026년 7월 8일 (14일 전 · 갱신 권장) |
추천 비교
추천 비교